By Katherine Hamilton
AEON Biopharma named Rob Bancroft as its new chief executive.
The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt.
Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics.
Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity.
Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 21, 2025 16:25 ET (20:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.